Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Cash from Financing Activities came in at -$8.8 million in Q1 2026, down 181.7% YoY from $10.8 million in Q1 2025, and down 3222.18% on a QoQ basis from -$266000.0 in Q4 2025.
Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Cash from Financing Activities data on file, last reported at -$8.8 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 181.7% year-over-year to -$8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 363.01% YoY) and the FY2025 annual result came in at $11.4 million, down 68.51% from the prior year.
- Cash from Financing Activities retreated to -$8.8 million in Q1 2026, from -$266000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $78.2 million in Q1 2022 to a low of -$8.8 million in Q1 2026.
- A 5-year average of $9.7 million and a median of $310000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 39224.8% in 2022, down 18800.0% in 2022.
- Tracing XERS's Cash from Financing Activities over 5 years: stood at $49.2 million in 2022, then slumped by 102.51% to -$1.2 million in 2023, then soared by 132.25% to $398000.0 in 2024, then tumbled by 166.83% to -$266000.0 in 2025, then tumbled by 3222.18% to -$8.8 million in 2026.
- The last three Cash from Financing Activities figures came in at -$8.8 million (Q1 2026), -$266000.0 (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Mn |
| Jun 30, 2026 | 1.94 Mn |
| Mar 31, 2026 | -8.84 Mn |
| Mar 31, 2026 | -8.84 Mn |
| Dec 31, 2025 | -266,000.00 |
| Dec 31, 2025 | -266,000.00 |
| Sep 30, 2025 | 13.85 Mn |
| Sep 30, 2025 | 13.85 Mn |
| Jun 30, 2025 | 942,000.00 |
| Jun 30, 2025 | 942,000.00 |
| Mar 31, 2025 | -3.14 Mn |
| Mar 31, 2025 | -3.14 Mn |
| Dec 31, 2024 | 398,000.00 |
| Dec 31, 2024 | 398,000.00 |
| Sep 30, 2024 | -83,000.00 |
| Sep 30, 2024 | -83,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Mar 31, 2024 | 35.19 Mn |
| Mar 31, 2024 | 35.19 Mn |